These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 20206881

  • 1. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
    Grigorescu-Sido P, Drugan C, Alkhzouz C, Zimmermann A, Coldea C, Denes C, Grigorescu MD, Cret V, Bucerzan S.
    Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
    [Abstract] [Full Text] [Related]

  • 2. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience.
    Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, Zimmermann A.
    J Inherit Metab Dis; 2007 Oct; 30(5):783-9. PubMed ID: 17703370
    [Abstract] [Full Text] [Related]

  • 3. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics.
    Giraldo P, Pocoví M, Pérez-Calvo J, Rubio-Félix D, Giralt M.
    Haematologica; 2000 Aug; 85(8):792-9. PubMed ID: 10942924
    [Abstract] [Full Text] [Related]

  • 4. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
    Duan YL, Zhang YH, Zang Y, Shi HP, Zhang WM, Hu YM.
    Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
    [Abstract] [Full Text] [Related]

  • 5. Baseline characteristics of 32 patients with Gaucher disease who were treated with imiglucerase: South African data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry.
    Sevittz H, Laher F, Varughese ST, Nel M, McMaster A, Jacobson BF.
    S Afr Med J; 2022 Feb 02; 112(1):13518. PubMed ID: 35140000
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul 02; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 7. Enzyme replacement therapy for Gaucher disease in Australia.
    Goldblatt J, Szer J, Fletcher JM, McGill J, Rowell JA, Wilson M.
    Intern Med J; 2005 Mar 02; 35(3):156-61. PubMed ID: 15737135
    [Abstract] [Full Text] [Related]

  • 8. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 02; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 9. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
    Wenstrup RJ, Kacena KA, Kaplan P, Pastores GM, Prakash-Cheng A, Zimran A, Hangartner TN.
    J Bone Miner Res; 2007 Jan 02; 22(1):119-26. PubMed ID: 17032149
    [Abstract] [Full Text] [Related]

  • 10. Long-term hematological, visceral, and growth outcomes in children with Gaucher disease type 3 treated with imiglucerase in the International Collaborative Gaucher Group Gaucher Registry.
    El-Beshlawy A, Tylki-Szymanska A, Vellodi A, Belmatoug N, Grabowski GA, Kolodny EH, Batista JL, Cox GF, Mistry PK.
    Mol Genet Metab; 2017 Jan 02; 120(1-2):47-56. PubMed ID: 28040394
    [Abstract] [Full Text] [Related]

  • 11. Long term effects of enzyme replacement therapy in an Italian cohort of type 3 Gaucher patients.
    Sechi A, Deroma L, Dardis A, Ciana G, Bertin N, Concolino D, Linari S, Perria C, Bembi B.
    Mol Genet Metab; 2014 Nov 02; 113(3):213-8. PubMed ID: 25127542
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1.
    Andersson H, Kaplan P, Kacena K, Yee J.
    Pediatrics; 2008 Dec 02; 122(6):1182-90. PubMed ID: 19047232
    [Abstract] [Full Text] [Related]

  • 15. Enzyme replacement therapy and bony changes in Egyptian paediatric Gaucher disease patients.
    El-Beshlawy A, Ragab L, Youssry I, Yakout K, El-Kiki H, Eid K, Mansour IM, Abd El-Hamid S, Yang M, Mistry PK.
    J Inherit Metab Dis; 2006 Feb 02; 29(1):92-8. PubMed ID: 16601874
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of Spanish Gaucher disease patients after a 6-month imiglucerase shortage.
    Giraldo P, Irún P, Alfonso P, Dalmau J, Fernández-Galán MA, Figueredo A, Hernández-Rivas JM, Julia A, Luño E, Marín-Jimenez F, Martín-Nuñez G, Montserrat JL, de la Serna J, Vidaller A, Villalón L, Pocovi M.
    Blood Cells Mol Dis; 2011 Jan 15; 46(1):115-8. PubMed ID: 20934891
    [Abstract] [Full Text] [Related]

  • 17. Evaluation of disease burden and response to treatment in adults with type 1 Gaucher disease using a validated disease severity scoring system (DS3).
    Weinreb NJ, Finegold DN, Feingold E, Zeng Z, Rosenbloom BE, Shankar SP, Amato D.
    Orphanet J Rare Dis; 2015 May 22; 10():64. PubMed ID: 25994334
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.